A Prospective NIS to Evaluate the Clinical Outcomes of Risarg® (Ribociclib) Combined With Endocrine Therapy or Chemotherapy in Patients With HR+HER2 - Advanced Breast Cancer in Routine Clinical Practice in the Russian Federation
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- HR+HER2- Advanced Breast Cancer
- Sponsor
- Novartis Pharmaceuticals
- Enrollment
- 376
- Locations
- 1
- Primary Endpoint
- time to treatment failure (TTF)
- Status
- Active, not recruiting
- Last Updated
- 4 months ago
Overview
Brief Summary
This is а prospective, non-interventional, primary data collection cohort study to evaluate the clinical outcomes of the combination of ribociclib + ET and combination chemotherapy in the real-life setting in Russia. This study is observational in nature; it does not impose a therapy, diagnostic/therapeutic interventions or a visit schedule.
Detailed Description
Patients with HR+HER2- advanced breast cancer that initiated treatment with ribociclib+ET or combination CT will be enrolled. Approximately, 188 patients will be included into each treatment cohort of the study across different study sites in the Russian Federation and will be assigned to one of the below treatment arms: * Ribociclib arm: ribociclib (600 mg, 3 weeks on/1 week off)+ IA/FUL + goserilin for premenopausal patients (N = 188) * Combination chemotherapy arm: physician's choice (N = 188) The study will consist of pre-index period, index date and follow up period. Retrospective data will be collected as such: Medical history, previous treatment for Breast cancer (neoad'uvant and ad'uvant if applicable).In this study an index date is defined as a start of ribociclib+ET or chemotherapy treatment. Post-index follow-up period is 24 months or Progressive disease. Patients will attend the sites in accordance with routine clinical practice. It is assumed according to the clinical practice that visits will be conducted every 3-4 months. Patients will undergo standard procedures and tests according to clinical guidelines and physician's judgement. No additional diagnostic or monitoring procedures will be applied to the patients and epidemiological methods shall be used for the analysis of collected data. Available data from routine clinical management of the patients will be collected at patients' visits to the clinical site. Patients enrolled in the study will be followed up until death or study close whichever occurs first.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age ≥ 18 years at the moment of ribociclib+ET or CT initiation.
- •Female/Male gender.
- •Luminal A, Luminal B subtype.
- •Patients with ECOG performance status ≤
- •Confirmed diagnosis of locally advanced/metastatic not eligible to surgery HR+HER2- BC (de novo) for whom the treating physician took the decision to initiate treatment with ribociclib+IA/FUL or combination chemotherapy before entering the study in the first line of the treatment.
- •Multiple visceral metastases (including stable CNS mts).
- •Pre-/Pere /postmenopause.
- •Patient who initiated treatment with ribociclib+IA/FUL or combination chemotherapy no longer than 4 weeks (28 days) prior to written informed consent for this study.
Exclusion Criteria
- •Patients with a life expectancy of less than 3 months per the investigator's judgment.
- •Patients participating in any interventional clinical trial that includes investigational or marketed products at the time of enrollment. (Patients participating in other investigator initiated research or NIS can be included as long as their standard of care is not altered by the study).
- •Patients on active treatment for malignancies other than aBC at the time of enrollment.
- •Patients who are unable to understand the nature of the study and are unwilling to sign an informed consent.
- •Patients with visceral crisis (according to ABC5 definition\*) \*Visceral crisis is defined as severe organ dysfunction, as assessed by signs and symptoms, laboratory studies and rapid progression of disease. Visceral crisis is not the mere presence of visceral metastases but implies important organ compromise leading to a clinical indication for the most rapidly efficacious therapy \[8\].
- •Examples: Liver visceral crisis: rapidly increasing bilirubin \>1.5 ULN in the absence of Gilbert's syndrome or biliary tract obstruction. Lung visceral crisis: rapidly increasing dyspnoea at rest, not alleviated by drainage of pleural effusion
Outcomes
Primary Outcomes
time to treatment failure (TTF)
Time Frame: Up to 24 months
The primary efficacy endpoint of the study is time to treatment failure (TTF) in in RIB + ET (AI/FUL) and combination chemotherapy cohorts. Time to treatment failure (TTF) is defined as the time from initiation of treatment to discontinuation of treatment for any reason, including disease progression, treatment toxicity, and death.
Secondary Outcomes
- Chemotherapy regimens(Up to 24 months)
- Clinical benefit rate (CBR)(Up to 24 months)
- Assessment of Quality of life - EQ-5D-5L(Up to 24 months)
- Number of participants by menopausal status(Baseline)
- Time to treatment failure (TTF) in the subgroups(Dec2027)
- Time to onset of response (TTR)(Up to 24 months)
- Number of participants by HER2 status(Baseline)
- Objective response rate (ORR)(Up to 24 months)
- Number of participants by tumor, nodes and metastasis (TNM) stage(Baseline)